Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

Blood

Volumn 99, Issue 10, 2002, Pages 3547-3553

  Kantarjian, Hagop M ^a,b,c   Cortes, Jorge ^a,b   O'Brien, Susan ^a,b   Giles, Francis J ^a,b   Albitar, Maher ^a,b   Rios, Mary Beth ^a,b   Shan, Jianqin ^a,b   Faderl, Stefan ^a,b   Garcia Manero, Guillermo ^a,b   Thomas, Deborah A ^a,b   Resta, Debra ^a,b   Talpaz, Moshe ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMATINIB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN TOXICITY;

EID: 0037092980     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3547     Document Type: Article

References (30)

1. Chronic myelogenous leukemia: A concise update
2. Treatment of chronic myelogenous leukemia: Current status and investigational options
3. Chronic myelogenous leukemia: Biology and therapy
4. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
5. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr
6. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
7. Chronic myelogenous leukemia in the lymphoid blastic phase: Characteristics, treatment response, and prognosis
8. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in blastic phase
9. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
10. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity
11. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
12. Selective inhibition of cell proliferation and BCR-ABL phophorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57184)
13. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
14. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia
15. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
16. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
17. A phase II study to determine the safety and anti-leukemic effects of imatinib mesylate in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
18. A phase II study to determine the safety and anti-leukemic effects of imatinib mesylate in adult patients with Philadelphia chromosome positive acute leukemias
19. Nonparametric estimation from incomplete observations
20. Evaluations of survival data and two new rank order statistics arising in its consideration
21. Analysis of survival by tumor response
22. Regression models and life tables
23. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
24. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
25. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
26. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase myelogenous leukemia
27. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
28. Clinical and biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
29. 3 enhances selective cytotoxic effects on STI-571 against Bcr-Abl-positive acute leukemia cells